Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Free Cash Flow (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Free Cash Flow for 17 consecutive years, with -$786848.0 as the latest value for Q1 2026.

  • Quarterly Free Cash Flow fell 54.32% to -$786848.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$4.8 million through Jan 2026, down 111.4% year-over-year, with the annual reading at -$3.0 million for FY2025, 38.43% down from the prior year.
  • Free Cash Flow for Q1 2026 was -$786848.0 at PharmaCyte Biotech, up from -$979523.0 in the prior quarter.
  • The five-year high for Free Cash Flow was $342959.0 in Q3 2023, with the low at -$2.0 million in Q3 2025.
  • Average Free Cash Flow over 5 years is -$833783.6, with a median of -$786848.0 recorded in 2026.
  • The sharpest move saw Free Cash Flow soared 131.63% in 2023, then plummeted 434.15% in 2025.
  • Over 5 years, Free Cash Flow stood at -$1.9 million in 2022, then fell by 5.59% to -$2.0 million in 2023, then soared by 46.85% to -$1.1 million in 2024, then increased by 7.13% to -$979523.0 in 2025, then rose by 19.67% to -$786848.0 in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$786848.0, -$979523.0, and -$2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.